Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR  + /HER2- advanced breast cancer

Conclusions  These results established an acceptable safety profile for FCN-437c in patients with advanced BC, and there were no unexpected signals relative to other CDK4/6 inhibitors. (NCT04488107; July 13, 2020)
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research